comprehensive -WSS

comprehensive

author：hotspot 2025-09-28 02:32:39 - browse：957

Ionis Pharmaceuticals, a California biotech that has spearheaded the development of RNA-targeting medicines, announced on Tuesday that its drug against familial chylomicronemia syndrome, a rare and serious disease that prevents the body from breaking down fats, succeeded in a late-stage clinical trial.

The Phase 3 trial, dubbed Balance, enrolled 66 adults who were randomly divided into three groups and given a monthly injection of placebo or one of two doses of olezarsen, the company’s experimental drug. Treatment with the higher dose of the therapy significantly lowered triglycerides in the blood of those on the drug for six months compared to participants given placebo, though a lower dose did not have this effect. Participants on the high dose didn’t have any instances of painful inflammation of the pancreas, one of the disease’s most serious symptoms, while there were 11 such episodes among those on placebo.

Researchers reported that the treatment was also generally safe, with fewer adverse events among those on olezarsen than among the placebo group.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： What does generative AI mean for health care? We asked experts
Next article： Pence says 'crackpot lawyers' told Trump what he wanted to hear

WSS

What could happen if Russia blows up the Zaporizhzhia Nuclear Power Plant?

Micronoma's microbiome cancer diagnostic approach under fire

Canadian Prime Minister Justin Trudeau separating from wife, Sophie

Mega Millions pot grows to $1.25 billion after no winner

Zelenskyy on how Russian invasion may end, gratitude for US aid and Putin's weakness

Tennessee woman gets emergency hysterectomy after doctors deny early abortion care

knowledge

comprehensive

leisure time

Medical records are filled with copy

National panel will explore requiring free Covid tests

United colonoscopy coverage change 'may cost lives,' doctors say

Florida group launches initiative to get abortion constitutional amendment on 2024 ballot

23andMe had bad news about my health. I wish a person had delivered it

Adults seen as increasingly susceptible to measles

Moonlake's readout produced a cash windfall. Risks remain

FDA approves Leqembi, a milestone in Alzheimer’s treatment

Activists slam private health insurers over coverage restrictions

UPS workers' union leader explains what's at stake as strike edges closer

focus

Breakthrough Alzheimer’s drugs are inaccessible in rural states

Neutralizing antibodies against HIV shows promise in children

What are cluster munitions? Biden defends decision to send controversial weapons to Ukraine

Trump seeks lengthy delay of classified docs trial, citing upcoming election

Physician groups backed by private equity giant lobby on mergers

Wildfire pollution widens asthma inequities on Long Island

focus

entertainment

hotspot

leisure time